Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.

Abstract

BACKGROUND\nThe study aimed to investigate the efficacy and safety outcomes in hormone-sensitive oligometastatic prostate cancer (OMPC) patients treated with docetaxel-based neoadjuvant chemohormonal therapy (NCHT) prior to radical prostatectomy (RP) compared with direct RP and standard androgen deprivation therapy (ADT) alone using propensity score match (PSM) analysis.\n\n\nPATIENTS AND METHODS\nA single-center, prospective, three-arm study was conducted with hormone-sensitive OMPC patients. Eligible patients (N\xa0=\xa0130) were divided into three groups-NCHT, RP, and standard treatment (ST)-and received their respective treatments. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were pathological response rate, radiographic progression-free survival (rPFS), and overall survival (OS). Further, propensity scores were calculated and group-wise comparisons were carried out: NCHT versus RP, ST versus RP, and ST versus NCHT.\n\n\nRESULTS\nAfter PSM, in the NCHT group, two patients (11.76%) and four patients (23.52%) had complete and partial pathological responses, respectively. Univariate and multivariate Cox regression analysis showed that PFS and rPFS were significantly higher in the NCHT group. For NCHT versus RP, the PFS hazard ratio (HR)\xa0=\xa00.11 (95% confidence interval [CI], 0.02-0.51; P\xa0=\xa0.004) and HR\xa0=\xa00.016 (95% CI, 0.0015-0.17; P < .001); the rPFS HR\xa0=\xa00.088 (95% CI, 0.011-0.71; P\xa0=\xa0.023) and HR\xa0=\xa00.03 (95% CI, 0.0025-0.36; P\xa0=\xa0.006). Further, the median OS of the ST group was 44.6 months for ST versus RP, and it was 49.3 months for ST versus NCHT; it was not reached in either the NCHT or RP group. Furthermore, 17.65% and 47.06% patients had positive surgical margins in the NCHT and RP groups, respectively, and no therapy-related deaths were observed during the study period.\n\n\nCONCLUSIONS\nPSM analysis revealed NCHT before RP in OMPC patients has potential therapeutic benefits with acceptable toxicities and lower incidence of postoperative positive surgical margins.